Nevertheless, several IDO1 inhibitors including indoximod and epacadostat are now undergoing Phase I/II clinical trials in cancer patients in whom induction of IDO and resulting evasion of anti-tumoral immune responses may play a role (70–72). The gene discussed is IDO1; the disease is cancer.